IACT Health, John B. Amos Cancer Center — Columbus, Georgia

IACT Health, John B. Amos Cancer Center is a clinical research site located in Columbus, Georgia, United States 31904.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

IACT Health, John B. Amos Cancer Center has participated in 3 clinical trials.

Therapeutic areas: Esophageal Squamous Cell Carcinoma, Solid Tumor, Adult, Squamous Cell Carcinoma of the Head and Neck.

Sponsors: Innovent Biologics (Suzhou) Co. Ltd., Trishula Therapeutics, Inc., EMD Serono Research & Development Institute, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Columbus

Browse all research sites in Georgia · View every site in Columbus

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for IACT Health, John B. Amos Cancer Center?

IACT Health, John B. Amos Cancer Center has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has IACT Health, John B. Amos Cancer Center conducted?

IACT Health, John B. Amos Cancer Center has 3 clinical trials on record. Their work covers Esophageal Squamous Cell Carcinoma, Solid Tumor, Adult, Squamous Cell Carcinoma of the Head and Neck.

Is IACT Health, John B. Amos Cancer Center accredited by Crixeo Clinical Trials?

IACT Health, John B. Amos Cancer Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about IACT Health, John B. Amos Cancer Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.